Compounds > 3-Acetyl-2,4-dimethylpyrrole
Page last updated: 2024-12-05

3-Acetyl-2,4-dimethylpyrrole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID15163
CHEMBL ID1725066
CHEBI ID194594
SCHEMBL ID891077

Synonyms (61)

Synonym
AC-6172
5-21-07-00235 (beilstein handbook reference)
ethanone, 1-(2,4-dimethyl-1h-pyrrol-3-yl)-
ketone, 2,4-dimethylpyrrol-3-yl methyl
brn 0109769
einecs 219-197-1
nsc 10759
ketone, 2,5-dimethyl-3-pyrrolyl methyl
ketone, 2,5-dimethylpyrrol-3-yl methyl
nsc 40231
2,5-dimethylpyrrol-3-yl methyl ketone
brn 0112096
ai3-60327
3-acetyl-2,5-dimethyl-pyrrole
smr000033154
1-(2,4-dimethyl-1h-pyrrol-3-yl)ethanone
MLS000047143
2,4-dimethylpyrrol-3-yl methyl ketone
3-acetyl-2,4-dimethylpyrrole
nsc-10759
ketone,4-dimethylpyrrol-3-yl methyl
2386-25-6
nsc10759
ethanone,4-dimethyl-1h-pyrrol-3-yl)-
2,4-dimethyl-3-acetylpyrrole
wln: t5mj b1 cv1 d1
inchi=1/c8h11no/c1-5-4-9-6(2)8(5)7(3)10/h4,9h,1-3h
3-acetyl-2,4-dimethylpyrrole, 97%
AKOS001094269
CHEBI:194594
A23298
STK792998
1-(2,4-dimethyl-1h-pyrrol-3-yl)ethan-1-one
5-21-07-00234 (beilstein handbook reference)
HMS2283D10
FT-0634238
S10046
SCHEMBL891077
1-(2,4-dimethyl-1h-pyrrole-3-yl)-ethanone
2,4-dimethyl-3 -acetyl-pyrrole
3- acetyl-2,4-dimethylpyrrole
2,4-dimethyl-3-acetyl pyrrole
3-acetyl-2,4-dimethyl-1h-pyrrole
1-(2,4-dimethyl-1h-pyrrol-3-yl)-ethanone
2,4-dimethyl-3-acetyl-pyrrole
2,4-dimethyl-3acetyl pyrrole
CHEMBL1725066
AS-59482
ethanone, 1-(2,5-dimethyl-1h-pyrrol-3-yl)- (9ci)
J-015242
mfcd00005221
763024-00-6
AMY18912
CS-0128744
1-(2,4-dimethyl-3h-pyrrol-3-ylidene)ethanol
SB62142
DTXSID60870963
EN300-13023
1-(2.4-dimethy- 1h-prrol-yl)-ethanone
SY051650
Z89264938
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
hypothetical protein, conservedTrypanosoma bruceiPotency39.81070.223911.245135.4813AID624173
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency3.35870.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency67.45550.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510